{{Drugbox
| IUPAC_name = (2''R'')-2-Methyl-6-nitro-2-[(4-<nowiki/>{4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-''b''][1,3]oxazole
| image = Delamanid.svg
| width = 325
| alt = 
| caption = 

<!-- Clinical data -->
| tradename = Deltyba
| Drugs.com = {{Drugs.com|international|delamanid}}
| MedlinePlus = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = by mouth (film-coated [[Tablet (pharmacy)|tablets]])

<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = ≥99.5%
| metabolism = in plasma by albumin, in liver<br />by [[CYP3A4]] (to a lesser extent)
| elimination_half-life = 30–38 hours
| excretion = not excreted in urine<ref>{{cite web|title=Deltyba (delamanid): Summary of Product Characteristics. 5.2. Pharmacokinetic Properties|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002552/WC500166232.pdf|publisher=Otsuka Novel Products GmbH|accessdate=9 July 2016|page=10|deadurl=no|archiveurl=https://web.archive.org/web/20160817012403/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002552/WC500166232.pdf|archivedate=17 August 2016|df=}}</ref>

<!-- Identifiers -->
| CAS_number = 681492-22-8
| ATCvet = 
| ATC_prefix = J04
| ATC_suffix = AK06
| PubChem = 6480466
| DrugBank = 
| ChemSpiderID = 4981055
| ChEMBL = 218650
| synonyms = OPC-67683
| KEGG = D09785
| UNII = 8OOT6M1PC7

<!-- Chemical data -->
| C = 25 | H = 25 | F = 3 | N = 4 | O = 6
| molecular_weight = 534.48 g/mol
| smiles = FC(F)(F)Oc5ccc(OC4CCN(c3ccc(OC[C@@]2(Oc1nc(cn1C2)[N+]([O-])=O)C)cc3)CC4)cc5
| StdInChI = 1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1
| StdInChIKey = XDAOLTSRNUSPPH-XMMPIXPASA-N
}}
<!-- Definition and medical uses -->
'''Delamanid''', sold under the brand name '''Deltyba''', is a medication used to treat [[tuberculosis]].<ref name=WHO2015Use/> Specifically it is used, along with other [[antituberculosis medication]]s, for active [[multidrug-resistant tuberculosis]].<ref name=WHO2015Use/> It is taken by mouth.<ref name=WHO2015Use>{{cite book|title=The selection and use of essential medicines: Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children).|date=2015|publisher=WHO|isbn=9789240694941|pages=29-31|url=http://apps.who.int/iris/bitstream/10665/189763/1/9789241209946_eng.pdf?ua=1|deadurl=no|archiveurl=https://web.archive.org/web/20161220085929/http://apps.who.int/iris/bitstream/10665/189763/1/9789241209946_eng.pdf?ua=1|archivedate=2016-12-20|df=}}</ref>

<!-- mechanism -->
Common side effects include headache, dizziness, and nausea.<ref name=World2016>{{cite book|title=Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions|date=2016|publisher=Elsevier|isbn=9780444638892|page=284|url=https://books.google.ca/books?id=km4kDAAAQBAJ&pg=PA284|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20161220092405/https://books.google.ca/books?id=km4kDAAAQBAJ&pg=PA284|archivedate=2016-12-20|df=}}</ref> Other side effects include [[QT prolongation]].<ref name=WHO2015Use/> It has not been studied in pregnancy as of 2016.<ref name=Coh2016>{{cite book|last1=Cohen|first1=Jonathan|last2=Powderly|first2=William G.|last3=Opal|first3=Steven M.|title=Infectious Diseases|date=2016|publisher=Elsevier Health Sciences|isbn=9780702063381|page=284|url=https://books.google.ca/books?id=Dhq3DAAAQBAJ&pg=PA284|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20161220092421/https://books.google.ca/books?id=Dhq3DAAAQBAJ&pg=PA284|archivedate=2016-12-20|df=}}</ref> Delamanid works by blocking the manufacture of [[mycolic acid]]s thus destabilising the bacteria's [[cell wall]].<ref>{{cite journal|last1=Blair|first1=HA|last2=Scott|first2=LJ|title=Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.|journal=Drugs|date=January 2015|volume=75|issue=1|pages=91-100|pmid=25404020}}</ref>

<!-- History and culture -->
Delamanid was approved for medical use in 2014 in Europe, Japan, and South Korea.<ref>{{cite book|last1=Fischer|first1=Janos|title=Successful Drug Discovery|date=2016|publisher=John Wiley & Sons|isbn=9783527341153|page=139|url=https://books.google.ca/books?id=S70cDQAAQBAJ&pg=PA139|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20161220092349/https://books.google.ca/books?id=S70cDQAAQBAJ&pg=PA139|archivedate=2016-12-20|df=}}</ref> It is on the [[World Health Organization's List of Essential Medicines]], the most effective and safe medicines needed in a [[health system]].<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}</ref> As of 2016 the [[Stop TB Partnership]] had an agreement to get the medication for 1,700 USD per six month for use in more than 100 countries.<ref name=TB2016>{{cite web|title=Stop TB Partnership {{!}} "Stop TB Partnership's Global Drug Facility jumpstarts access to new drugs for MDR-TB with innovative public-private partnerships|url=http://www.stoptb.org/news/stories/2016/ns16_005.asp|website=www.stoptb.org|accessdate=15 January 2017|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20170116172033/http://www.stoptb.org/news/stories/2016/ns16_005.asp|archivedate=16 January 2017|df=}}</ref>

==Medical uses==

Delamanid is used, along with other [[antituberculosis medication]]s, for active [[multidrug-resistant tuberculosis]].<ref name=WHO2015Use/>

==Adverse effects==
Common side effects include headache, dizziness, and nausea.<ref name=World2016/> Other side effects include [[QT prolongation]].<ref name=WHO2015Use/> It has not been studied in pregnancy as of 2016.<ref name=Coh2016/>

Delamanid [[QT prolongation|prolongs the QT interval]].<ref name="PZ">Pharmazeutische Zeitung: [http://www.pharmazeutische-zeitung.de/index.php?id=52126 Delamanid: Neuer Wirkstoff gegen multiresistente TB] {{webarchive|url=https://web.archive.org/web/20150924091734/http://www.pharmazeutische-zeitung.de/index.php?id=52126 |date=2015-09-24 }}, 9 May 2014. {{de icon}}</ref>

==Interactions==
Delamanid is metabolised by the liver enzyme [[CYP3A4]]; therefore strong inducers of this enzyme can reduce its effectiveness.<ref name="PZ" />

==History==
In phase II [[clinical trial]]s, the drug was used in combination with standard treatments, such as four or five of the drugs [[ethambutol]], [[isoniazid]], [[pyrazinamide]], [[rifampicin]], [[aminoglycoside antibiotic]]s, and [[Quinolone antibiotic|quinolones]]. Healing rates (measured as sputum [[culture conversion]]) were significantly better in patients who additionally took delamanid.<ref name="Spreitzer">{{cite journal| author = H. Spreitzer| date = 18 February 2013| title = Neue Wirkstoffe – [[Bedaquiline|Bedaquilin]] und Delamanid| journal = Österreichische Apothekerzeitung| issue = 4/2013| page = 22| language = German}}</ref><ref>{{Cite journal | last1 = Gler | first1 = M. T. | last2 = Skripconoka | first2 = V. | last3 = Sanchez-Garavito | first3 = E. | last4 = Xiao | first4 = H. | last5 = Cabrera-Rivero | first5 = J. L. | last6 = Vargas-Vasquez | first6 = D. E. | last7 = Gao | first7 = M. | last8 = Awad | first8 = M. | last9 = Park | first9 = S. K. | last10 = Shim | doi = 10.1056/NEJMoa1112433 | first10 = T. S. | last11 = Suh | first11 = G. Y. | last12 = Danilovits | first12 = M. | last13 = Ogata | first13 = H. | last14 = Kurve | first14 = A. | last15 = Chang | first15 = J. | last16 = Suzuki | first16 = K. | last17 = Tupasi | first17 = T. | last18 = Koh | first18 = W. J. | last19 = Seaworth | first19 = B. | last20 = Geiter | first20 = L. J. | last21 = Wells | first21 = C. D. | title = Delamanid for Multidrug-Resistant Pulmonary Tuberculosis | journal = New England Journal of Medicine | volume = 366 | issue = 23 | pages = 2151–2160 | year = 2012 | pmid = 22670901 | pmc = }}</ref>

The [[European Medicines Agency]] (EMA) recommended conditional marketing authorization for delamanid in adults with multidrug-resistant pulmonary tuberculosis without other treatment options because of resistance or tolerability.  The EMA considered the data show that the benefits of delamanid outweigh the risks, but that additional studies were needed on the long-term effectiveness.<ref>Drug Discovery & Development. [http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001972.jsp&mid=WC0b01ac058004d5c1 EMA Recommends Two New Tuberculosis Treatments.] {{webarchive|url=https://web.archive.org/web/20131203022613/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2013%2F11%2Fnews_detail_001972.jsp&mid=WC0b01ac058004d5c1 |date=2013-12-03 }} November 22, 2013.</ref>

==Society and culture==
The medication was not readily available globally as of 2015.<!-- <ref name=WHO2015Use/> --> It was believed that pricing will be similar to [[bedaquiline]], which for six months is approximately 900 USD in low income countries, 3,000 USD in middle income countries, and 30,000 USD in high income countries.<ref name=WHO2015Use/> As of 2016 the [[Stop TB Partnership]] had an agreement to get the medication for 1,700 USD per six month.<ref name=TB2016/>

==See also==
* [[Pretomanid]], a related drug

==References==
{{reflist|32em}}

{{Antimycobacterials}}

[[Category:Anti-tuberculosis drugs]]
[[Category:World Health Organization essential medicines]]
[[Category:RTT]]
[[Category:Trifluoromethyl compounds]]